



## **ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020**

August 12, 2020

SAN DIEGO--(BUSINESS WIRE)--Aug. 12, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.

The conference will be held virtually. A live webcast of ACADIA's presentation will be accessible on the company's website, [www.acadia-pharm.com](http://www.acadia-pharm.com), under the investors section and an archived recording will be available on the website through September 19, 2020.

### *About ACADIA Pharmaceuticals*

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's development efforts are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: [www.acadia-pharm.com](http://www.acadia-pharm.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200812005131/en/): <https://www.businesswire.com/news/home/20200812005131/en/>

### *Media Contact:*

ACADIA Pharmaceuticals Inc.  
Eric Endicott  
(858) 914-7161  
[media@acadia-pharm.com](mailto:media@acadia-pharm.com)

### *Investor Contact:*

ACADIA Pharmaceuticals Inc.  
Mark Johnson, CFA  
(858) 261-2771  
[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)

Source: ACADIA Pharmaceuticals Inc.